Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
7.09
+1.28 (22.03%)
At close: Nov 9, 2026, 4:00 PM EST
7.24
+0.15 (2.12%)
After-hours: Nov 9, 2026, 6:00 PM EST
Exagen Revenue
Exagen had revenue of $19.94M in the quarter ending June 30, 2026, with 15.92% growth. This brings the company's total for the last twelve months to $71.12M, up 20.83% year-over-year. In the year 2025, Exagen had annual revenue of $66.58M with 19.65% growth. That makes Exagen the 25,321st largest company in the world by revenue and 3,521st in the United States.
Revenue (ttm)
$71.12M
Revenue Growth
+20.83%
P/S Ratio
2.11
Revenue / Employee
$323,282
Employees
220
Market Cap
171.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.58M | 10.93M | 19.65% |
| Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
| Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
| Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
| Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
| Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
| Dec 31, 2019 | 40.39M | 7.95M | 24.50% |
| Dec 31, 2018 | 32.44M | 5.63M | 21.01% |
| Dec 31, 2017 | 26.81M | 8.86M | 49.38% |
| Dec 31, 2015 | 17.95M | 6.28M | 53.87% |
| Dec 31, 2014 | 11.66M | 8.61M | 281.77% |
| Dec 31, 2013 | 3.06M | 2.13M | 229.91% |
| Dec 31, 2012 | 926.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 803.60M |
| OPKO Health | 654.10M |
| Castle Biosciences | 377.13M |
| Fulgent Genetics | 330.28M |
| MDxHealth | 114.02M |
| Biodesix | 105.21M |
| Burning Rock Biotech | 73.70M |
| Freenome | 35.41M |
XGN News
- 11 days ago - Exagen Inc. to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - Exagen to Announce Third Quarter Financial Results on November 10, 2026 - GlobeNewsWire
- 21 days ago - Exagen price target raised to $11 from $9 at Canaccord - TheFly
- 27 days ago - Exagen price target raised to $11 from $10 at TD Cowen - TheFly
- 1 month ago - Exagen transferred with Buy rating at B. Riley - TheFly
- 2 months ago - Exagen participates in a conference call with Craig-Hallum - TheFly
- 3 months ago - Exagen Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 3 months ago - Exagen price target raised to $9 from $8 at BTIG - TheFly